ASCRS 2024: IOLs, binocularity and stereoacuity in aperture optics

News
Video

William F. Wiley, MD, shares key takeaways from his presentation on binocularity and stereoacuity

At ASCRS 2024, William F. Wiley, MD, shared key takeaways from his presentation on binocularity and aperture optics with Ophthalmology Times. Here's what he had to say about his research.

Video Transcript

Editor's note - This transcript has been edited for clarity.

William F. Wiley, MD: Hi, Dr. William Wiley here at ASCRS in Boston. I'm the medical director of Cleveland Eye Clinic, and here I'm giving a presentation on binocularity and aperture optics.

As we know, when looking at monovision, we treat a lot of patients with traditional monovision—one eye set for distance and one eye set for a little bit better up-close vision. Typically, to get a good near effect you might have to target -150 to get that monovision near effect. However, what we notice [is], yes, you do get near vision, but you often lose stereoacuity when you target too near.

What we found, though, is with aperture optics, that aperture allows you to target less near, so you can target about -75 with an aperture optic. It's going to deliver the near vision, intermediate, and maintain some of the distance vision. So, you're going to have maintenance of distance vision, but picking up intermediate and near vision. And, also, you don't lose that stereoacuity effect like you see with traditional monovision.

So, with the aperture monovision, more or less, you're getting distance, intermediate and near without sacrificing stereoacuity.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.